Loading clinical trials...

Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc) | Clinical Trials | Clareo Health

COMPLETEDNA

Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc)

Self-Guided Resilience-Building Energy Management to Enhance Well-being Intervention for People With Systemic Sclerosis: A Feasibility Study

NCT07402863•University of Michigan

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to gather information on the RENEW app used by people with scleroderma. Specifically, the researchers want to learn more about RENEW by collecting information about the rates of recruitment, retention of study participants information about study completion, and time spent accessing the app content.

Detailed Description

RENEW is Institutional Review Board approved as a non-significant risk device but it not subject to 510(k) and therefore not regulated by the FDA.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Have a diagnosis of systemic sclerosis including: diffuse cutaneous SSc, limited cutaneous SSc, overlap, or SINE
•Have access to a reliable, internet-connected device (e.g. smartphone or tablet)
•Be able to read, speak, and understand English
•Participants need to report a score of at least 4 on a scale of 0 - 10 of fatigue severity, a cut-off for at least moderate fatigue in other fatiguing conditions1

Exclusion Criteria

•Complex, unstable health issues that would preclude full participation in the study
•Planning to start new treatment for fatigue, pain, mood during the study period
•Previous experience with RENEW app or past participant of RENEW

Locations (1)

University of Michigan

Ann Arbor, Michigan, United States

Key Dates

Start Date

January 28, 2025

Primary Completion Date

April 28, 2025

Completion Date

July 28, 2025

Last Updated

February 11, 2026

Enrollment

ACTUAL participants

Conditions

Systemic Sclerosis

Interventions

RENEW

DEVICE

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

NCT06947460

Refractory Lupus NephritisSystemic Sclerosis+1 more

View study

RECRUITINGPHASE1

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

NCT07413341

Systemic Lupus Erythematosus (SLE)Sjogren's Syndrome (SS)+3 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 11, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Self-Guided Resilience-Building Energy Management to Enhance Well-being (RENEW) Intervention for People With Systemic Sclerosis (SSc)

Inclusion Criteria

Exclusion Criteria

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Rheumatology Patient Registry and Biorepository

A Study of AZD0120 in Autoimmune Diseases

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases